Protective Effect of Obeticholic Acid on Sepsis-Induced Liver Dysfunction via Regulating Bile Acid Homeostasis.

IF 4.3 3区 医学 Q2 CHEMISTRY, MEDICINAL
Pharmaceuticals Pub Date : 2025-05-21 DOI:10.3390/ph18050763
Jiahui Wang, Li Ma, Yuan An, Yan Ge, Dan Xu, Enqiang Mao
{"title":"Protective Effect of Obeticholic Acid on Sepsis-Induced Liver Dysfunction via Regulating Bile Acid Homeostasis.","authors":"Jiahui Wang, Li Ma, Yuan An, Yan Ge, Dan Xu, Enqiang Mao","doi":"10.3390/ph18050763","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives:</b> Abnormal bile acid (BA) pool may play an important role in inducing liver damage in sepsis. Farnesoid X receptor (FXR) is a main negative feedback regulator of BA metabolism. This study aims to explore the protective effect and mechanism of the FXR agonist obeticholic acid (OCA) on liver dysfunction when sepsis occurs. <b>Methods:</b> A rat model of sepsis was induced by cecal ligation and puncture (CLP) for 24 h. Systematic inflammation, tissue injury, hepatic FXR, and BA transporter expression were investigated in the CLP rats and sham-operated control rats with and without OCA pre-treatment (10 mg/kg, gavage) at 2 h before operation. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was performed to access BA composition in the rats' serum and livers. The injury and inflammatory effects of the elevated unconjugated BAs found in the CLP rats was further verified in a hepatic cell line BRL-3A in vitro. <b>Results:</b> Hepatic FXR was repressed in CLP rats, whereas OCA upregulated liver FXR and hepatic BA transporter expression, reduced total serum BA concentration, ameliorated the elevation of serum levels of IL-1β and IL-6, and improved liver and ileal tissue injuries. OCA administration reduced the elevated unconjugated BAs in both serum and liver, and effectively inhibited increases in cholic acid (CA), deoxycholic acid (DCA), and 7-ketoDCA concentrations in CLP rat livers. These BA fractions promoted the release of aspartate aminotransferase (AST) from BRL-3A cells and increased IL-6, CXCL2, and monocyte chemoattractant protein-1 (MCP-1) expression in the cells, along with enhanced transcription factor nuclear factor-κB activation. <b>Conclusions:</b> Liver inflammation and dysfunction during sepsis is attributable to significant changes in bile acid composition in the blood and liver. FXR activation reduces systemic inflammation and liver dysfunction by regulating bile acid homeostasis, especially inflammatory unconjugated bile acid components.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"18 5","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12114768/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ph18050763","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background/Objectives: Abnormal bile acid (BA) pool may play an important role in inducing liver damage in sepsis. Farnesoid X receptor (FXR) is a main negative feedback regulator of BA metabolism. This study aims to explore the protective effect and mechanism of the FXR agonist obeticholic acid (OCA) on liver dysfunction when sepsis occurs. Methods: A rat model of sepsis was induced by cecal ligation and puncture (CLP) for 24 h. Systematic inflammation, tissue injury, hepatic FXR, and BA transporter expression were investigated in the CLP rats and sham-operated control rats with and without OCA pre-treatment (10 mg/kg, gavage) at 2 h before operation. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was performed to access BA composition in the rats' serum and livers. The injury and inflammatory effects of the elevated unconjugated BAs found in the CLP rats was further verified in a hepatic cell line BRL-3A in vitro. Results: Hepatic FXR was repressed in CLP rats, whereas OCA upregulated liver FXR and hepatic BA transporter expression, reduced total serum BA concentration, ameliorated the elevation of serum levels of IL-1β and IL-6, and improved liver and ileal tissue injuries. OCA administration reduced the elevated unconjugated BAs in both serum and liver, and effectively inhibited increases in cholic acid (CA), deoxycholic acid (DCA), and 7-ketoDCA concentrations in CLP rat livers. These BA fractions promoted the release of aspartate aminotransferase (AST) from BRL-3A cells and increased IL-6, CXCL2, and monocyte chemoattractant protein-1 (MCP-1) expression in the cells, along with enhanced transcription factor nuclear factor-κB activation. Conclusions: Liver inflammation and dysfunction during sepsis is attributable to significant changes in bile acid composition in the blood and liver. FXR activation reduces systemic inflammation and liver dysfunction by regulating bile acid homeostasis, especially inflammatory unconjugated bile acid components.

奥贝胆酸通过调节胆汁酸稳态对败血症肝功能障碍的保护作用。
背景/目的:胆汁酸(BA)池异常可能在脓毒症的肝损害诱导中起重要作用。Farnesoid X受体(FXR)是BA代谢的主要负反馈调节因子。本研究旨在探讨FXR激动剂奥贝胆酸(OCA)对脓毒症时肝功能障碍的保护作用及机制。方法:采用盲肠结扎穿刺法(CLP)建立脓毒症大鼠模型24 h,在术前2 h观察OCA预处理(10 mg/kg,灌胃)对CLP大鼠和假手术对照大鼠的全身炎症、组织损伤、肝脏FXR和BA转运体表达的影响。采用液相色谱-串联质谱法(LC-MS/MS)测定大鼠血清和肝脏中BA的组成。在体外肝细胞系BRL-3A中进一步验证了在CLP大鼠中发现的升高的非偶联BAs的损伤和炎症作用。结果:CLP大鼠肝脏FXR受到抑制,而OCA上调肝脏FXR和肝脏BA转运蛋白表达,降低血清总BA浓度,改善血清IL-1β和IL-6水平升高,改善肝脏和回肠组织损伤。OCA可降低血清和肝脏中未结合的BAs升高,并有效抑制CLP大鼠肝脏中胆酸(CA)、去氧胆酸(DCA)和7-酮DCA浓度的升高。这些BA组分促进BRL-3A细胞中天冬氨酸转氨酶(AST)的释放,增加细胞中IL-6、CXCL2和单核细胞趋化蛋白-1 (MCP-1)的表达,并增强转录因子核因子-κB的激活。结论:脓毒症时肝脏炎症和功能障碍可归因于血液和肝脏中胆汁酸成分的显著变化。FXR激活通过调节胆汁酸稳态,特别是炎性非共轭胆汁酸成分,减少全身炎症和肝功能障碍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceuticals
Pharmaceuticals Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
6.10
自引率
4.30%
发文量
1332
审稿时长
6 weeks
期刊介绍: Pharmaceuticals (ISSN 1424-8247) is an international scientific journal of medicinal chemistry and related drug sciences.Our aim is to publish updated reviews as well as research articles with comprehensive theoretical and experimental details. Short communications are also accepted; therefore, there is no restriction on the maximum length of the papers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信